论文部分内容阅读
放射性n 125I粒子植入治疗技术已被广泛应用各种恶性肿瘤的综合治疗中。近年来核医学开展的放射性n 125I粒子植入治疗量逐年增加，成为核素治疗的重要项目。为了推进及规范核医学放射性n 125I粒子植入治疗工作、加强质量控制、开展大数据研究及多学科合作以及规范临床治疗，中华医学会核医学分会治疗学组组织了治疗学组放射性粒子介入治疗工作委员会部分专家，借鉴目前国内外指南及最新研究，参考相关法律法规，结合我国临床现状，起草制定本共识。本共识包括一般要求、质量管理控制、防护要求3个部分。放射性n 125I粒子植入治疗作为放射性介入治疗，具有核素介入临床技术及放射性核素管理二重特点，本共识通过在技术质量控制和放射性核素管理2个方面进行规范，从根本上逐步解决粒子植入治疗领域的问题，以提高治疗效果，促进放射性n 125I粒子植入治疗工作的顺利开展。n “,”Radioactive n 125I seeds implantation has been widely used in the comprehensive treatment of various malignant tumors. In recent years, the amount of radioactive n 125I seeds implantation therapy in nuclear medicine has increased year by year, which has become an important project of radionuclide therapy. In order to promote and standardize the treatment of radioactive n 125I seeds implantation in nuclear medicine, strengthen quality control, carry out big data research and multidisciplinary cooperation, and standardize clinical treatment, the Therapeutic Group of Chinese Society of Nuclear Medicine has organized some experts of the Working Committee of Therapeutic Group Radioactive Particle Interventional Therapy to formulate the expert consensus, which draws lessons from the current guidelines and latest researches at home and abroad, as well as relevant laws and regulations, combined with the clinical situation of our country. The consensus includes three parts: general requirements, quality management control, and protection requirements. Radioactive n 125I seed implantation therapy, as a radioactive interventional therapy, has the dual characteristics of radionuclide intervention clinical technology and radionuclide management. The consensus standardizes in two aspects of technical quality control and radionuclide management, and fundamentally solves the problems in the field of seed implantation therapy, thus improving the therapeutic effect and promoting the smooth development of radionuclide n 125I seed implantation therapy.n